Earlier: Immutep Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
Earlier: Immutep Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha ("efti"), a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel.
— Immutep Limited（（澳大利亚证券交易所股票代码：IMM，纳斯达克股票代码：IMMP）（“Immutep” 或 “公司”）是一家开发针对癌症和自身免疫性疾病的新型 LAG-3 免疫疗法的临床阶段生物技术公司，今天宣布了在欧洲肿瘤内科学会（ESMO）乳腺癌上发布的 AIPAC-003 II/III 期试验的安全性准备中获得的令人鼓舞的功效、安全性和药效学数据 2024 年国会。该前导药物是有史以来首次给药 90 毫克的依替拉吉莫德 α（“efti”），一种可溶的 LAG-3 蛋白，也是 MHC II 类激动剂，与每周一次的紫杉醇联合给药。